Sunder Mudaliar

University of San Diego — United States

Medicine · Health Sciences

57h-index15.4kcitations170works2.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Diabetes Treatment and Management(58), Metabolism, Diabetes, and Cancer(57), Diabetes Management and Research(35), Pancreatic function and diabetes(27), Adipose Tissue and Metabolism(27)

Publications158 total

Differences in Prevalence and Incidence of Electrocardiogram Abnormalities and Cardiovascular Autonomic Neuropathy Among Randomized Glucose-Lowering Treatments in Early Type 2 Diabetes: The Glycemia Reduction Approaches in Diabetes (GRADE) Cohort
Diabetes Care·2025Open Access
Impact of Parental or First-Degree Family History of Diabetes on Diabetes Incidence and Progression During Long-term Follow-up in the Diabetes Prevention Program Outcomes Study
Diabetes Care·2025Open Access
<b>Impact of Parental or First-Degree Family History of Diabetes on Diabetes Incidence and Progression during Long-term Follow-up in the Diabetes Prevention Program Outcomes Study</b>
2025Open Access
Longitudinal Metabolic Trajectories in Diabetes Prevention Program Participants Reveal Subgroups With Varying Micro- and Macrovascular Complication Risks
Diabetes Care·2025· 2 citedOpen Access
2094-LB: Electrocardiogram Abnormalities in Relatively Early Type 2 Diabetes—Prevalence and Incidence in the Glycemia Reduction Approaches in Diabetes (GRADE) Cohort
Diabetes·2025
Weight Gain Was Associated With Worsening Glycemia and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes Independent of Diabetes Medication in the GRADE Randomized Controlled Trial
Diabetes Care·2025· 1 cited
Weight gain was associated with worsening glycemia and cardiovascular and kidney outcomes in type 2 diabetes patients independent of diabetes medication in the GRADE Randomized Controlled Trial
2025Open Access
Weight gain was associated with worsening glycemia and cardiovascular and kidney outcomes in type 2 diabetes patients independent of diabetes medication in the GRADE Randomized Controlled Trial
2025Open Access
Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study)
Circulation·2024· 19 citedOpen Access
Type 2 Diabetes Moderates the Association Between Amyloid and 1-Year Change in Everyday Functioning in Older Veterans
Journal of Alzheimer s Disease·2023Open Access
Impact of type 2 diabetes on the association between amyloid and 1‐year change in everyday functioning in older Veterans
Alzheimer s & Dementia·2023Open Access
3 Type 2 Diabetes Moderates the Association between Amyloid PET and Attention/Executive Functioning in Older Veterans
Journal of the International Neuropsychological Society·2023Open Access
Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes
JAMA Internal Medicine·2023· 31 citedOpen Access
Astaxanthin, a natural antioxidant, lowers cholesterol and markers of cardiovascular risk in individuals with prediabetes and dyslipidaemia
Diabetes Obesity and Metabolism·2023· 37 citedOpen Access
Author response for "Astaxanthin, a Natural Antioxidant, Lowers Cholesterol and Markers of Cardiovascular Risk in Individuals with Prediabetes and Dyslipidemia"
2023
Author response for "Astaxanthin, a Natural Antioxidant, Lowers Cholesterol and Markers of Cardiovascular Risk in Individuals with Prediabetes and Dyslipidemia"
2023
Increase in hematocrit with SGLT-2 inhibitors - Hemoconcentration from diuresis or increased erythropoiesis after amelioration of hypoxia?
Diabetes & Metabolic Syndrome Clinical Research & Reviews·2022· 28 cited
Adipose tissue from subjects with type 2 diabetes exhibits impaired capillary formation in response to GROα: involvement of MMPs-2 and -9
Adipocyte·2022· 4 citedOpen Access
Sodium‐glucose co‐transporter‐2 inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice
Diabetes Obesity and Metabolism·2022· 37 citedOpen Access
Author response for "Sodium‐glucose cotransporter‐2 ( <scp>SGLT</scp> ‐2) inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice"
2022
page 1 of 8Next →

Frequent Co-authors

Robert R. Henry(42), Theodore P. Ciaraldi(22), Peter D. Reaven(7), Svetlana E. Nikoulina(7), Dawn C. Schwenke(6), Ralph A. DeFronzo(5), Devjit Tripathy(5), George A. Bray(5), Abbas E. Kitabchi(5), Robert E. Ratner(5), Kyong Soo Park(5), Thomas A. Buchanan(4), Stephen Clement(4), Frankie B. Stentz(4), Nicolas Musi(4), Leslie Carter(4), Sunita Baxi(4), Neelima V. Chu(4), Alice P.S. Kong(4), Dennis Dong Hwan Kim(3)